Indapamide to slow disability in progressive MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests an oral medication, indapamide, to see if it can slow down disability progression in people with progressive multiple sclerosis (MS). It may help by protecting nerve cells and reducing damage in the brain and spinal cord.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a diagnosis of primary or secondary progressive MS (PPMS or SPMS).
- Your disability level is moderate, as measured by a standard scale (EDSS score between 4.0 and 6.5).
- You can walk at least a short distance, but walking is slower than normal (specific time thresholds apply).
- If you are a woman who can have children, you must use effective birth control.
- You must not have certain health issues like severe kidney problems, low blood pressure, or heart rhythm problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a simple, non-invasive treatment called remote ischemic conditioning — using brief cycles of a blood pressure cuff on your arm — can improve walking and slow disability in people with primary progressive MS. It targets people with moderate disability who have trouble walking.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
This study looks at people with relapsing-remitting multiple sclerosis (RRMS) to find factors that predict disability progression even when they are not having relapses. It may help doctors understand who is at higher risk and guide treatment decisions.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.